文献速递心力衰竭与心肌病

新诊断与慢性心衰加重住院患者的比较:ASCEND-HF 试验分析

Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial.
PubMed 文献 · J Am Coll Cardiol · 2017-01-01

基于 ASCEND-HF 试验中 5,741 例有明确心衰病程记录的住院急性心衰患者,按诊断病程分为≤1 个月、>1–12 个月、>12–60 个月和>60 个月四组。与新诊断患者相比,病程更长者 24 小时持续呼吸困难风险更高、180 天死亡风险增加;新诊断(≤1 个月)与更早呼吸困难缓解和出院后生存改善独立相关。

要点

  • 新诊断心衰患者更多为女性、非缺血性病因、基线血压较高且合并症较少。
  • 病程>1 个月者 24 小时持续呼吸困难风险均高于新诊断患者。
  • 病程>1 个月者 180 天死亡风险约为新诊断患者的 1.8–2.0 倍。

核心结论

  • 心衰诊断病程≤1 个月与住院后更早的呼吸困难缓解及出院后生存改善独立相关。
  • 未来急性心衰试验设计应考虑区分新诊断心衰与慢性心衰加重。

研究设计与样本

  • ASCEND-HF 试验随机纳入 7,141 例急性心衰住院患者,接受奈西立肽或安慰剂加标准治疗。
  • 本分析按预设切点(0–1 个月、>1–12 个月、>12–60 个月、>60 个月)比较 5,741 例有病程记录患者的特征与结局。

主要发现

  • 各组平均年龄 64–66 岁,平均射血分数 29%–32%。
  • 与新诊断患者相比,>1–12 个月组 24 小时持续呼吸困难 OR 为 1.20(95%CI 0.97–1.48)。
  • >12–60 个月组 24 小时持续呼吸困难 OR 为 1.34(95%CI 1.11–1.62),>60 个月组 OR 为 1.31(95%CI 1.08–1.60)。
  • 与新诊断患者相比,>1–12 个月组 180 天死亡 HR 为 1.89(95%CI 1.35–2.65)。
  • >12–60 个月组 180 天死亡 HR 为 1.82(95%CI 1.33–2.48),>60 个月组 HR 为 2.02(95%CI 1.47–2.77)。

关键数值与推荐

  • 病程对新诊断后死亡的影响在女性中可能更明显(交互作用 p=0.05)。
  • 病程对死亡的影响按年龄、种族、既往缺血性心脏病或射血分数分层无差异(交互作用 p≥0.23)。

临床怎么用

  • 入院时应记录心衰诊断病程,以识别新诊断与慢性心衰加重患者的不同风险。
  • 对病程>1 个月的慢性心衰加重患者,需关注持续呼吸困难和出院后死亡风险升高。

局限性

  • 本研究为 ASCEND-HF 试验的事后分析,结果需在其它队列中验证。
  • 仅 80.4%(5,741/7,141)患者有明确心衰病程记录。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: It is unclear how patients hospitalized for acute heart failure (HF) who are long-term chronic HF survivors differ from those with more recent HF diagnoses. OBJECTIVES: The goal of this study was to evaluate the influence of HF chronicity on acute HF patient profiles and outcomes. METHODS: The ASCEND-HF (Acute Study of Clinical Effectiveness of Nesiritide in Decompensated Heart Failure) trial randomized 7,141 hospitalized patients with acute HF with reduced or preserved ejection fraction (EF) to receive nesiritide or placebo in addition to standard care. The present analysis compared patients according to duration of HF diagnosis before index hospitalization by using pre-specified cutoffs (0 to 1 month [i.e., "recently diagnosed"], >1 to 12 months, >12 to 60 months, and >60 months). RESULTS: Overall, 5,741 (80.4%) patients had documentation of duration of HF diagnosis (recently diagnosed, n = 1,536; >1 to 12 months, n = 1,020; >12 to 60 months, n = 1,653; and >60 months, n = 1,532). Across HF duration groups, mean age ranged from 64 to 66 years, and mean ejection fraction ranged from 29% to 32%. Compared with patients with longer HF duration, recently diagnosed patients were more likely to be women with nonischemic HF etiology, higher baseline blood pressure, better baseline renal function, and fewer comorbidities. After adjustment, compared with recently diagnosed patients, patients with longer HF duration were associated with more persistent dyspnea at 24 h (>1 to 12 months, odds ratio [OR]: 1.20; 95% confidence interval [CI]: 0.97 to 1.48; >12 to 60 months, OR: 1.34; 95% CI: 1.11 to 1.62; and >60 months, OR: 1.31; 95% CI: 1.08 to 1.60) and increased 180-day mortality (>1 to 12 months, hazard ratio [HR]: 1.89; 95% CI: 1.35 to 2.65; >12 to 60 months, HR: 1.82; 95% CI: 1.33 to 2.48; and >60 months, HR: 2.02; 95% CI: 1.47 to 2.77). The influence of HF duration on mortality was potentially more pronounced among female patients (interaction p = 0.05), but did not differ according to age, race, prior ischemic heart disease, or ejection fraction (all interactions, p ≥ 0.23). CONCLUSIONS: In this acute HF trial, patient profile differed according to duration of the HF diagnosis. A diagnosis of HF for ≤1 month before hospitalization was independently associated with greater early dyspnea relief and improved post-discharge survival compared to patients with chronic HF diagnoses. The distinction between de novo or recently diagnosed HF and worsening chronic HF should be considered in the design of future acute HF trials. (A Study Testing the Effectiveness of Nesiritide in Patients With Acute Decompensated Heart Failure; NCT00475852).

来源:J Am Coll Cardiol,查看原文。版权归原作者所有。

引用

  1. Greene SJ, Hernandez AF, Dunning A, et al. Hospitalization for Recently Diagnosed Versus Worsening Chronic Heart Failure: From the ASCEND-HF Trial. J Am Coll Cardiol. 2017. PMID: 28641792. doi:10.1016/j.jacc.2017.04.043

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。